Page last updated: 2024-09-05

sorafenib and npi 2358

sorafenib has been researched along with npi 2358 in 1 studies

Compound Research Comparison

Studies
(sorafenib)
Trials
(sorafenib)
Recent Studies (post-2010)
(sorafenib)
Studies
(npi 2358)
Trials
(npi 2358)
Recent Studies (post-2010) (npi 2358)
6,5207305,25136431

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)npi 2358 (IC50)
Tubulin alpha-1A chainSus scrofa (pig)1.8
Tubulin beta chainSus scrofa (pig)1.8
RAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)8.9
Mitogen-activated protein kinase 10Rattus norvegicus (Norway rat)6.8
Tubulin beta-2B chainBos taurus (cattle)2.4
Similar to alpha-tubulin isoform 1 Bos taurus (cattle)2.4
Similar to alpha-tubulin isoform 1 Bos taurus (cattle)2.4

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Deng, M; Li, L; Li, W; Yuan, S; Zhao, J1

Other Studies

1 other study(ies) available for sorafenib and npi 2358

ArticleYear
Antitumor activity of the microtubule inhibitor MBRI-001 against human hepatocellular carcinoma as monotherapy or in combination with sorafenib.
    Cancer chemotherapy and pharmacology, 2018, Volume: 81, Issue:5

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Diketopiperazines; Drug Synergism; Humans; Liver Neoplasms; Mice, Nude; Microtubules; Sorafenib; Xenograft Model Antitumor Assays

2018